19:06 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Biscayne reports Phase Ib data for epilepsy candidate BIS-001ER

Biscayne Neurotherapeutics Inc. (Miami, Fla.) reported data from a Phase Ib trial in 11 healthy volunteers showing that twice-daily 0.5-2.5 mg doses of epilepsy candidate BIS-001ER were well tolerated with no dose-limiting toxicities (DLTs) reported....
20:29 , Feb 3, 2017 |  BC Week In Review  |  Company News

Biscayne Pharmaceuticals deal

Biscayne Pharmaceuticals spun out CNS company Biscayne Neurotherapeutics Inc. (Miami, Fla.). The newco's sole asset is BIS-001 , which is in development to treat refractory forms of epilepsy, including partial complex seizures and Dravet syndrome....
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Biscayne Pharmaceuticals, Insero Health deal

Biscayne merged with Insero on June 30. Biscayne is developing growth hormone-releasing hormone (GHRH) receptor analogs. Biscayne’s lead compound is BIS-001, a selective acetylcholinesterace (AChE) inhibitor that has completed a Phase I trial in adults...